Comparative Pharmacology
Head-to-head clinical analysis: ADAPALENE versus ALTRENO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADAPALENE versus ALTRENO.
ADAPALENE vs ALTRENO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoic acid receptor agonist; binds to RARβ/γ nuclear receptors, modulating gene expression to normalize follicular keratinization and reduce comedogenesis.
Unknown; believed to involve reduction of hepatic glucose production and improvement of insulin sensitivity via AMPK activation.
Apply a pea-sized amount topically to affected areas once daily in the evening.
ALTRENO is not a recognized drug. No data available.
None Documented
None Documented
The terminal elimination half-life of adapalene after topical application is approximately 17 hours (range 7–51 hours), reflecting slow release from skin depot and hepatic clearance. This supports once-daily dosing.
Clinical Note
moderateAdapalene + Gatifloxacin
"Adapalene may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateAdapalene + Rosoxacin
"Adapalene may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateAdapalene + Levofloxacin
"Adapalene may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateAdapalene + Trovafloxacin
"Adapalene may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life is 20-30 hours; steady state reached in 5-7 days.
Adapalene is eliminated primarily via biliary excretion into feces. After oral administration in animals, approximately 80% of the dose is recovered in feces and about 10% in urine; for topical application, systemic absorption is minimal and the small absorbed fraction undergoes similar hepatobiliary elimination.
Primarily renal (70-80% as unchanged drug), with 10-15% biliary/fecal elimination.
Category D/X
Category C
Retinoid
Retinoid